Advertisement

Index by author

October 01, 1993; Volume 44,Issue 4

A

  1. Abdel-Razzak, Z

    1. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture.
      Z Abdel-Razzak, P Loyer, A Fautrel, J C Gautier, L Corcos, B Turlin, P Beaune and A Guillouzo
      Molecular Pharmacology October 1993, 44 (4) 707-715;

  2. Adams, M E

    1. Structure and properties of omega-agatoxin IVB, a new antagonist of P-type calcium channels.
      M E Adams, I M Mintz, M D Reily, V Thanabal and B P Bean
      Molecular Pharmacology October 1993, 44 (4) 681-688;

  3. Adesnik, M

    1. The phenobarbital-induced transcriptional activation of cytochrome P-450 genes is blocked by the glucocorticoid-progesterone antagonist RU486.
      P M Shaw, M Adesnik, M C Weiss and L Corcos
      Molecular Pharmacology October 1993, 44 (4) 775-783;

  4. Aguayo, L

    1. Ethanol inhibits a neuronal ATP-gated ion channel.
      C Li, L Aguayo, R W Peoples and F F Weight
      Molecular Pharmacology October 1993, 44 (4) 871-875;

  5. Anthony, N M

    1. Drosophila nervous system muscarinic acetylcholine receptor: transient functional expression and localization by immunocytochemistry.
      A D Blake, N M Anthony, H H Chen, J B Harrison, N M Nathanson and D B Sattelle
      Molecular Pharmacology October 1993, 44 (4) 716-724;

B

  1. Baba, M

    1. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442.
      S Yuasa, Y Sadakata, H Takashima, K Sekiya, N Inouye, M Ubasawa and M Baba
      Molecular Pharmacology October 1993, 44 (4) 895-900;

  2. Bai, R

    1. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin.
      R Bai, Z A Cichacz, C L Herald, G R Pettit and E Hamel
      Molecular Pharmacology October 1993, 44 (4) 757-766;

  3. Balzarini, J

    1. Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
      J Balzarini, A Karlsson and E De Clercq
      Molecular Pharmacology October 1993, 44 (4) 694-701;

  4. Barker, E L

    1. 5-hydroxytryptamine1C receptor density and mRNA levels in choroid plexus epithelial cells after treatment with mianserin and (-)-1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane.
      E L Barker and E Sanders-Bush
      Molecular Pharmacology October 1993, 44 (4) 725-730;

  5. Bascands, J L

    1. Indirect inhibition by bradykinin of cyclic AMP generation in isolated rat glomeruli and mesangial cells.
      J L Bascands, C Pecher and J P Girolami
      Molecular Pharmacology October 1993, 44 (4) 818-826;

  6. Battey, J F

    1. Discovery of a novel class of neuromedin B receptor antagonists, substituted somatostatin analogues.
      M Orbuch, J E Taylor, D H Coy, J E Mrozinski, S A Mantey, J F Battey, J P Moreau and R T Jensen
      Molecular Pharmacology October 1993, 44 (4) 841-850;

  7. Bean, B P

    1. Structure and properties of omega-agatoxin IVB, a new antagonist of P-type calcium channels.
      M E Adams, I M Mintz, M D Reily, V Thanabal and B P Bean
      Molecular Pharmacology October 1993, 44 (4) 681-688;

  8. Beaune, P

    1. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture.
      Z Abdel-Razzak, P Loyer, A Fautrel, J C Gautier, L Corcos, B Turlin, P Beaune and A Guillouzo
      Molecular Pharmacology October 1993, 44 (4) 707-715;

  9. Blake, A D

    1. Drosophila nervous system muscarinic acetylcholine receptor: transient functional expression and localization by immunocytochemistry.
      A D Blake, N M Anthony, H H Chen, J B Harrison, N M Nathanson and D B Sattelle
      Molecular Pharmacology October 1993, 44 (4) 716-724;

  10. Breivogel, C S

    1. Modification of G protein-coupled functions by low-pH pretreatment of membranes from NG108-15 cells: increase in opioid agonist efficacy by decreased inactivation of G proteins.
      D E Selley, C S Breivogel and S R Childers
      Molecular Pharmacology October 1993, 44 (4) 731-741;

C

  1. Carter, D B

    1. U-93631 causes rapid decay of gamma-aminobutyric acid-induced chloride currents in recombinant rat gamma-aminobutyric acid type A receptors.
      G H Dillon, H K Im, B J Hamilton, D B Carter, R B Gammill, T M Judge and W B Im
      Molecular Pharmacology October 1993, 44 (4) 860-865;
    2. Potentiation of gamma-aminobutyric acid-induced chloride currents by various benzodiazepine site agonists with the alpha 1 gamma 2, beta 2 gamma 2 and alpha 1 beta 2 gamma 2 subtypes of cloned gamma-aminobutyric acid type A receptors.
      H K Im, W B Im, B J Hamilton, D B Carter and P F Vonvoigtlander
      Molecular Pharmacology October 1993, 44 (4) 866-870;

  2. Challiss, R A

    1. Inositol-1,3,4,5-tetrakisphosphate induces calcium mobilization via the inositol-1,4,5-trisphosphate receptor in SH-SY5Y neuroblastoma cells.
      R A Wilcox, R A Challiss, C Liu, B V Potter and S R Nahorski
      Molecular Pharmacology October 1993, 44 (4) 810-817;

  3. Chang, K J

    1. BW373U86: a nonpeptidic delta-opioid agonist with novel receptor-G protein-mediated actions in rat brain membranes and neuroblastoma cells.
      S R Childers, L M Fleming, D E Selley, R W McNutt and K J Chang
      Molecular Pharmacology October 1993, 44 (4) 827-834;

  4. Chen, C

    1. Beta-[3H]funaltrexamine-labeled mu-opioid receptors: species variations in molecular mass and glycosylation by complex-type, N-linked oligosaccharides.
      L Y Liu-Chen, C Chen and C A Phillips
      Molecular Pharmacology October 1993, 44 (4) 749-756;

  5. Chen, H H

    1. Drosophila nervous system muscarinic acetylcholine receptor: transient functional expression and localization by immunocytochemistry.
      A D Blake, N M Anthony, H H Chen, J B Harrison, N M Nathanson and D B Sattelle
      Molecular Pharmacology October 1993, 44 (4) 716-724;

  6. Childers, S R

    1. Modification of G protein-coupled functions by low-pH pretreatment of membranes from NG108-15 cells: increase in opioid agonist efficacy by decreased inactivation of G proteins.
      D E Selley, C S Breivogel and S R Childers
      Molecular Pharmacology October 1993, 44 (4) 731-741;
    2. BW373U86: a nonpeptidic delta-opioid agonist with novel receptor-G protein-mediated actions in rat brain membranes and neuroblastoma cells.
      S R Childers, L M Fleming, D E Selley, R W McNutt and K J Chang
      Molecular Pharmacology October 1993, 44 (4) 827-834;

  7. Cichacz, Z A

    1. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin.
      R Bai, Z A Cichacz, C L Herald, G R Pettit and E Hamel
      Molecular Pharmacology October 1993, 44 (4) 757-766;

  8. Corcos, L

    1. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture.
      Z Abdel-Razzak, P Loyer, A Fautrel, J C Gautier, L Corcos, B Turlin, P Beaune and A Guillouzo
      Molecular Pharmacology October 1993, 44 (4) 707-715;
    2. The phenobarbital-induced transcriptional activation of cytochrome P-450 genes is blocked by the glucocorticoid-progesterone antagonist RU486.
      P M Shaw, M Adesnik, M C Weiss and L Corcos
      Molecular Pharmacology October 1993, 44 (4) 775-783;

  9. Coy, D H

    1. Discovery of a novel class of neuromedin B receptor antagonists, substituted somatostatin analogues.
      M Orbuch, J E Taylor, D H Coy, J E Mrozinski, S A Mantey, J F Battey, J P Moreau and R T Jensen
      Molecular Pharmacology October 1993, 44 (4) 841-850;

D

  1. Davies, M F

    1. Zinc selectively inhibits flux through benzodiazepine-insensitive gamma-aminobutyric acid chloride channels in cortical and cerebellar microsacs.
      M F Davies, P A Maguire and G H Loew
      Molecular Pharmacology October 1993, 44 (4) 876-881;

  2. De Clercq, E

    1. Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
      J Balzarini, A Karlsson and E De Clercq
      Molecular Pharmacology October 1993, 44 (4) 694-701;

  3. DeYoung, M B

    1. Coupling of expressed alpha 1B- and alpha 1D-adrenergic receptor to multiple signaling pathways is both G protein and cell type specific.
      D M Perez, M B DeYoung and R M Graham
      Molecular Pharmacology October 1993, 44 (4) 784-795;

  4. Dillon, G H

    1. U-93631 causes rapid decay of gamma-aminobutyric acid-induced chloride currents in recombinant rat gamma-aminobutyric acid type A receptors.
      G H Dillon, H K Im, B J Hamilton, D B Carter, R B Gammill, T M Judge and W B Im
      Molecular Pharmacology October 1993, 44 (4) 860-865;

E

  1. Eriks, J C

    1. New activation model for the histamine H2 receptor, explaining the activity of the different classes of histamine H2 receptor agonists.
      J C Eriks, H van der Goot and H Timmerman
      Molecular Pharmacology October 1993, 44 (4) 886-894;

F

  1. Fautrel, A

    1. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture.
      Z Abdel-Razzak, P Loyer, A Fautrel, J C Gautier, L Corcos, B Turlin, P Beaune and A Guillouzo
      Molecular Pharmacology October 1993, 44 (4) 707-715;

  2. Fleming, L M

    1. BW373U86: a nonpeptidic delta-opioid agonist with novel receptor-G protein-mediated actions in rat brain membranes and neuroblastoma cells.
      S R Childers, L M Fleming, D E Selley, R W McNutt and K J Chang
      Molecular Pharmacology October 1993, 44 (4) 827-834;

G

  1. Gammill, R B

    1. U-93631 causes rapid decay of gamma-aminobutyric acid-induced chloride currents in recombinant rat gamma-aminobutyric acid type A receptors.
      G H Dillon, H K Im, B J Hamilton, D B Carter, R B Gammill, T M Judge and W B Im
      Molecular Pharmacology October 1993, 44 (4) 860-865;

  2. Gautier, J C

    1. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture.
      Z Abdel-Razzak, P Loyer, A Fautrel, J C Gautier, L Corcos, B Turlin, P Beaune and A Guillouzo
      Molecular Pharmacology October 1993, 44 (4) 707-715;

  3. Gioannini, T L

    1. Antisera against peptides derived from a purified mu-opioid binding protein recognize the protein as well as mu-opioid receptors in brain regions and a cell line.
      T L Gioannini, Y H Yao, J M Hiller, L P Taylor and E J Simon
      Molecular Pharmacology October 1993, 44 (4) 796-801;

  4. Girolami, J P

    1. Indirect inhibition by bradykinin of cyclic AMP generation in isolated rat glomeruli and mesangial cells.
      J L Bascands, C Pecher and J P Girolami
      Molecular Pharmacology October 1993, 44 (4) 818-826;

  5. Graham, R M

    1. Coupling of expressed alpha 1B- and alpha 1D-adrenergic receptor to multiple signaling pathways is both G protein and cell type specific.
      D M Perez, M B DeYoung and R M Graham
      Molecular Pharmacology October 1993, 44 (4) 784-795;

  6. Green, R D

    1. Calcium entry via L-type calcium channels acts as a negative regulator of adenylyl cyclase activity and cyclic AMP levels in cardiac myocytes.
      H J Yu, H Ma and R D Green
      Molecular Pharmacology October 1993, 44 (4) 689-693;

  7. Guillouzo, A

    1. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture.
      Z Abdel-Razzak, P Loyer, A Fautrel, J C Gautier, L Corcos, B Turlin, P Beaune and A Guillouzo
      Molecular Pharmacology October 1993, 44 (4) 707-715;

H

  1. Hamel, E

    1. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin.
      R Bai, Z A Cichacz, C L Herald, G R Pettit and E Hamel
      Molecular Pharmacology October 1993, 44 (4) 757-766;

  2. Hamilton, B J

    1. U-93631 causes rapid decay of gamma-aminobutyric acid-induced chloride currents in recombinant rat gamma-aminobutyric acid type A receptors.
      G H Dillon, H K Im, B J Hamilton, D B Carter, R B Gammill, T M Judge and W B Im
      Molecular Pharmacology October 1993, 44 (4) 860-865;
    2. Potentiation of gamma-aminobutyric acid-induced chloride currents by various benzodiazepine site agonists with the alpha 1 gamma 2, beta 2 gamma 2 and alpha 1 beta 2 gamma 2 subtypes of cloned gamma-aminobutyric acid type A receptors.
      H K Im, W B Im, B J Hamilton, D B Carter and P F Vonvoigtlander
      Molecular Pharmacology October 1993, 44 (4) 866-870;

  3. Harrison, J B

    1. Drosophila nervous system muscarinic acetylcholine receptor: transient functional expression and localization by immunocytochemistry.
      A D Blake, N M Anthony, H H Chen, J B Harrison, N M Nathanson and D B Sattelle
      Molecular Pharmacology October 1993, 44 (4) 716-724;

  4. Herald, C L

    1. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin.
      R Bai, Z A Cichacz, C L Herald, G R Pettit and E Hamel
      Molecular Pharmacology October 1993, 44 (4) 757-766;

  5. Hiller, J M

    1. Antisera against peptides derived from a purified mu-opioid binding protein recognize the protein as well as mu-opioid receptors in brain regions and a cell line.
      T L Gioannini, Y H Yao, J M Hiller, L P Taylor and E J Simon
      Molecular Pharmacology October 1993, 44 (4) 796-801;

  6. Hobbs, G A

    1. Anti-human immunodeficiency virus type 1 therapy and peripheral neuropathy: prevention of 2',3'-dideoxycytidine toxicity in PC12 cells, a neuronal model, by uridine and pyruvate.
      S A Keilbaugh, G A Hobbs and M V Simpson
      Molecular Pharmacology October 1993, 44 (4) 702-706;

I

  1. Im, H K

    1. U-93631 causes rapid decay of gamma-aminobutyric acid-induced chloride currents in recombinant rat gamma-aminobutyric acid type A receptors.
      G H Dillon, H K Im, B J Hamilton, D B Carter, R B Gammill, T M Judge and W B Im
      Molecular Pharmacology October 1993, 44 (4) 860-865;
    2. Potentiation of gamma-aminobutyric acid-induced chloride currents by various benzodiazepine site agonists with the alpha 1 gamma 2, beta 2 gamma 2 and alpha 1 beta 2 gamma 2 subtypes of cloned gamma-aminobutyric acid type A receptors.
      H K Im, W B Im, B J Hamilton, D B Carter and P F Vonvoigtlander
      Molecular Pharmacology October 1993, 44 (4) 866-870;

  2. Im, W B

    1. U-93631 causes rapid decay of gamma-aminobutyric acid-induced chloride currents in recombinant rat gamma-aminobutyric acid type A receptors.
      G H Dillon, H K Im, B J Hamilton, D B Carter, R B Gammill, T M Judge and W B Im
      Molecular Pharmacology October 1993, 44 (4) 860-865;
    2. Potentiation of gamma-aminobutyric acid-induced chloride currents by various benzodiazepine site agonists with the alpha 1 gamma 2, beta 2 gamma 2 and alpha 1 beta 2 gamma 2 subtypes of cloned gamma-aminobutyric acid type A receptors.
      H K Im, W B Im, B J Hamilton, D B Carter and P F Vonvoigtlander
      Molecular Pharmacology October 1993, 44 (4) 866-870;

  3. Inouye, N

    1. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442.
      S Yuasa, Y Sadakata, H Takashima, K Sekiya, N Inouye, M Ubasawa and M Baba
      Molecular Pharmacology October 1993, 44 (4) 895-900;

J

  1. Jensen, R T

    1. Discovery of a novel class of neuromedin B receptor antagonists, substituted somatostatin analogues.
      M Orbuch, J E Taylor, D H Coy, J E Mrozinski, S A Mantey, J F Battey, J P Moreau and R T Jensen
      Molecular Pharmacology October 1993, 44 (4) 841-850;

  2. Judge, T M

    1. U-93631 causes rapid decay of gamma-aminobutyric acid-induced chloride currents in recombinant rat gamma-aminobutyric acid type A receptors.
      G H Dillon, H K Im, B J Hamilton, D B Carter, R B Gammill, T M Judge and W B Im
      Molecular Pharmacology October 1993, 44 (4) 860-865;

K

  1. Karlsson, A

    1. Human immunodeficiency virus type 1 drug-resistance patterns with different 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
      J Balzarini, A Karlsson and E De Clercq
      Molecular Pharmacology October 1993, 44 (4) 694-701;

  2. Keilbaugh, S A

    1. Anti-human immunodeficiency virus type 1 therapy and peripheral neuropathy: prevention of 2',3'-dideoxycytidine toxicity in PC12 cells, a neuronal model, by uridine and pyruvate.
      S A Keilbaugh, G A Hobbs and M V Simpson
      Molecular Pharmacology October 1993, 44 (4) 702-706;

L

  1. Lavelle, F

    1. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
      B Poddevin, J F Riou, F Lavelle and Y Pommier
      Molecular Pharmacology October 1993, 44 (4) 767-774;

  2. Li, C

    1. Ethanol inhibits a neuronal ATP-gated ion channel.
      C Li, L Aguayo, R W Peoples and F F Weight
      Molecular Pharmacology October 1993, 44 (4) 871-875;

  3. Li, Y

    1. Biochemical and immunochemical comparison of saxiphilin and transferrin, two structurally related plasma proteins from Rana catesbeiana.
      Y Li, L Llewellyn and E Moczydlowski
      Molecular Pharmacology October 1993, 44 (4) 742-748;

  4. Liu, C

    1. Inositol-1,3,4,5-tetrakisphosphate induces calcium mobilization via the inositol-1,4,5-trisphosphate receptor in SH-SY5Y neuroblastoma cells.
      R A Wilcox, R A Challiss, C Liu, B V Potter and S R Nahorski
      Molecular Pharmacology October 1993, 44 (4) 810-817;

  5. Liu-Chen, L Y

    1. Beta-[3H]funaltrexamine-labeled mu-opioid receptors: species variations in molecular mass and glycosylation by complex-type, N-linked oligosaccharides.
      L Y Liu-Chen, C Chen and C A Phillips
      Molecular Pharmacology October 1993, 44 (4) 749-756;

  6. Llewellyn, L

    1. Biochemical and immunochemical comparison of saxiphilin and transferrin, two structurally related plasma proteins from Rana catesbeiana.
      Y Li, L Llewellyn and E Moczydlowski
      Molecular Pharmacology October 1993, 44 (4) 742-748;

  7. Loew, G H

    1. Zinc selectively inhibits flux through benzodiazepine-insensitive gamma-aminobutyric acid chloride channels in cortical and cerebellar microsacs.
      M F Davies, P A Maguire and G H Loew
      Molecular Pharmacology October 1993, 44 (4) 876-881;

  8. Loyer, P

    1. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture.
      Z Abdel-Razzak, P Loyer, A Fautrel, J C Gautier, L Corcos, B Turlin, P Beaune and A Guillouzo
      Molecular Pharmacology October 1993, 44 (4) 707-715;

M

  1. Ma, H

    1. Calcium entry via L-type calcium channels acts as a negative regulator of adenylyl cyclase activity and cyclic AMP levels in cardiac myocytes.
      H J Yu, H Ma and R D Green
      Molecular Pharmacology October 1993, 44 (4) 689-693;

  2. Maguire, P A

    1. Zinc selectively inhibits flux through benzodiazepine-insensitive gamma-aminobutyric acid chloride channels in cortical and cerebellar microsacs.
      M F Davies, P A Maguire and G H Loew
      Molecular Pharmacology October 1993, 44 (4) 876-881;

  3. Mantey, S A

    1. Discovery of a novel class of neuromedin B receptor antagonists, substituted somatostatin analogues.
      M Orbuch, J E Taylor, D H Coy, J E Mrozinski, S A Mantey, J F Battey, J P Moreau and R T Jensen
      Molecular Pharmacology October 1993, 44 (4) 841-850;

  4. Maren, T H

    1. Chemical properties of carbonic anhydrase IV, the membrane-bound enzyme.
      T H Maren, G C Wynns and P J Wistrand
      Molecular Pharmacology October 1993, 44 (4) 901-905;

  5. McNutt, R W

    1. BW373U86: a nonpeptidic delta-opioid agonist with novel receptor-G protein-mediated actions in rat brain membranes and neuroblastoma cells.
      S R Childers, L M Fleming, D E Selley, R W McNutt and K J Chang
      Molecular Pharmacology October 1993, 44 (4) 827-834;

  6. Mintz, I M

    1. Structure and properties of omega-agatoxin IVB, a new antagonist of P-type calcium channels.
      M E Adams, I M Mintz, M D Reily, V Thanabal and B P Bean
      Molecular Pharmacology October 1993, 44 (4) 681-688;

  7. Moczydlowski, E

    1. Biochemical and immunochemical comparison of saxiphilin and transferrin, two structurally related plasma proteins from Rana catesbeiana.
      Y Li, L Llewellyn and E Moczydlowski
      Molecular Pharmacology October 1993, 44 (4) 742-748;

  8. Moreau, J P

    1. Discovery of a novel class of neuromedin B receptor antagonists, substituted somatostatin analogues.
      M Orbuch, J E Taylor, D H Coy, J E Mrozinski, S A Mantey, J F Battey, J P Moreau and R T Jensen
      Molecular Pharmacology October 1993, 44 (4) 841-850;

  9. Mrozinski, J E

    1. Discovery of a novel class of neuromedin B receptor antagonists, substituted somatostatin analogues.
      M Orbuch, J E Taylor, D H Coy, J E Mrozinski, S A Mantey, J F Battey, J P Moreau and R T Jensen
      Molecular Pharmacology October 1993, 44 (4) 841-850;

N

  1. Nahorski, S R

    1. Inositol-1,3,4,5-tetrakisphosphate induces calcium mobilization via the inositol-1,4,5-trisphosphate receptor in SH-SY5Y neuroblastoma cells.
      R A Wilcox, R A Challiss, C Liu, B V Potter and S R Nahorski
      Molecular Pharmacology October 1993, 44 (4) 810-817;

  2. Nathanson, N M

    1. Drosophila nervous system muscarinic acetylcholine receptor: transient functional expression and localization by immunocytochemistry.
      A D Blake, N M Anthony, H H Chen, J B Harrison, N M Nathanson and D B Sattelle
      Molecular Pharmacology October 1993, 44 (4) 716-724;

O

  1. Orbuch, M

    1. Discovery of a novel class of neuromedin B receptor antagonists, substituted somatostatin analogues.
      M Orbuch, J E Taylor, D H Coy, J E Mrozinski, S A Mantey, J F Battey, J P Moreau and R T Jensen
      Molecular Pharmacology October 1993, 44 (4) 841-850;

  2. Osman, R

    1. Role of threonine 342 in helix 7 of the 5-hydroxytryptamine type 1D receptor in ligand binding: an indirect mechanism for receptor selectivity.
      A Smolyar and R Osman
      Molecular Pharmacology October 1993, 44 (4) 882-885;

P

  1. Pecher, C

    1. Indirect inhibition by bradykinin of cyclic AMP generation in isolated rat glomeruli and mesangial cells.
      J L Bascands, C Pecher and J P Girolami
      Molecular Pharmacology October 1993, 44 (4) 818-826;

  2. Peoples, R W

    1. Ethanol inhibits a neuronal ATP-gated ion channel.
      C Li, L Aguayo, R W Peoples and F F Weight
      Molecular Pharmacology October 1993, 44 (4) 871-875;

  3. Pepperl, D J

    1. Selective coupling of alpha 2-adrenergic receptor subtypes to cyclic AMP-dependent reporter gene expression in transiently transfected JEG-3 cells.
      D J Pepperl and J W Regan
      Molecular Pharmacology October 1993, 44 (4) 802-809;

  4. Perez, D M

    1. Coupling of expressed alpha 1B- and alpha 1D-adrenergic receptor to multiple signaling pathways is both G protein and cell type specific.
      D M Perez, M B DeYoung and R M Graham
      Molecular Pharmacology October 1993, 44 (4) 784-795;

  5. Pettit, G R

    1. Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin.
      R Bai, Z A Cichacz, C L Herald, G R Pettit and E Hamel
      Molecular Pharmacology October 1993, 44 (4) 757-766;

  6. Phillips, C A

    1. Beta-[3H]funaltrexamine-labeled mu-opioid receptors: species variations in molecular mass and glycosylation by complex-type, N-linked oligosaccharides.
      L Y Liu-Chen, C Chen and C A Phillips
      Molecular Pharmacology October 1993, 44 (4) 749-756;

  7. Poddevin, B

    1. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
      B Poddevin, J F Riou, F Lavelle and Y Pommier
      Molecular Pharmacology October 1993, 44 (4) 767-774;

  8. Pommier, Y

    1. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
      B Poddevin, J F Riou, F Lavelle and Y Pommier
      Molecular Pharmacology October 1993, 44 (4) 767-774;

  9. Potter, B V

    1. Inositol-1,3,4,5-tetrakisphosphate induces calcium mobilization via the inositol-1,4,5-trisphosphate receptor in SH-SY5Y neuroblastoma cells.
      R A Wilcox, R A Challiss, C Liu, B V Potter and S R Nahorski
      Molecular Pharmacology October 1993, 44 (4) 810-817;

R

  1. Redman, R S

    1. A selective adenosine antagonist (8-cyclopentyl-1,3-dipropylxanthine) eliminates both neuromuscular depression and the action of exogenous adenosine by an effect on A1 receptors.
      R S Redman and E M Silinsky
      Molecular Pharmacology October 1993, 44 (4) 835-840;

  2. Regan, J W

    1. Selective coupling of alpha 2-adrenergic receptor subtypes to cyclic AMP-dependent reporter gene expression in transiently transfected JEG-3 cells.
      D J Pepperl and J W Regan
      Molecular Pharmacology October 1993, 44 (4) 802-809;

  3. Reily, M D

    1. Structure and properties of omega-agatoxin IVB, a new antagonist of P-type calcium channels.
      M E Adams, I M Mintz, M D Reily, V Thanabal and B P Bean
      Molecular Pharmacology October 1993, 44 (4) 681-688;

  4. Riou, J F

    1. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials.
      B Poddevin, J F Riou, F Lavelle and Y Pommier
      Molecular Pharmacology October 1993, 44 (4) 767-774;

S

  1. Sadakata, Y

    1. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442.
      S Yuasa, Y Sadakata, H Takashima, K Sekiya, N Inouye, M Ubasawa and M Baba
      Molecular Pharmacology October 1993, 44 (4) 895-900;

  2. Sanders-Bush, E

    1. 5-hydroxytryptamine1C receptor density and mRNA levels in choroid plexus epithelial cells after treatment with mianserin and (-)-1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane.
      E L Barker and E Sanders-Bush
      Molecular Pharmacology October 1993, 44 (4) 725-730;

  3. Sattelle, D B

    1. Drosophila nervous system muscarinic acetylcholine receptor: transient functional expression and localization by immunocytochemistry.
      A D Blake, N M Anthony, H H Chen, J B Harrison, N M Nathanson and D B Sattelle
      Molecular Pharmacology October 1993, 44 (4) 716-724;

  4. Sekiya, K

    1. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442.
      S Yuasa, Y Sadakata, H Takashima, K Sekiya, N Inouye, M Ubasawa and M Baba
      Molecular Pharmacology October 1993, 44 (4) 895-900;

  5. Selley, D E

    1. Modification of G protein-coupled functions by low-pH pretreatment of membranes from NG108-15 cells: increase in opioid agonist efficacy by decreased inactivation of G proteins.
      D E Selley, C S Breivogel and S R Childers
      Molecular Pharmacology October 1993, 44 (4) 731-741;
    2. BW373U86: a nonpeptidic delta-opioid agonist with novel receptor-G protein-mediated actions in rat brain membranes and neuroblastoma cells.
      S R Childers, L M Fleming, D E Selley, R W McNutt and K J Chang
      Molecular Pharmacology October 1993, 44 (4) 827-834;

  6. Shaw, P M

    1. The phenobarbital-induced transcriptional activation of cytochrome P-450 genes is blocked by the glucocorticoid-progesterone antagonist RU486.
      P M Shaw, M Adesnik, M C Weiss and L Corcos
      Molecular Pharmacology October 1993, 44 (4) 775-783;

  7. Silinsky, E M

    1. A selective adenosine antagonist (8-cyclopentyl-1,3-dipropylxanthine) eliminates both neuromuscular depression and the action of exogenous adenosine by an effect on A1 receptors.
      R S Redman and E M Silinsky
      Molecular Pharmacology October 1993, 44 (4) 835-840;

  8. Simon, E J

    1. Antisera against peptides derived from a purified mu-opioid binding protein recognize the protein as well as mu-opioid receptors in brain regions and a cell line.
      T L Gioannini, Y H Yao, J M Hiller, L P Taylor and E J Simon
      Molecular Pharmacology October 1993, 44 (4) 796-801;

  9. Simpson, M V

    1. Anti-human immunodeficiency virus type 1 therapy and peripheral neuropathy: prevention of 2',3'-dideoxycytidine toxicity in PC12 cells, a neuronal model, by uridine and pyruvate.
      S A Keilbaugh, G A Hobbs and M V Simpson
      Molecular Pharmacology October 1993, 44 (4) 702-706;

  10. Smolyar, A

    1. Role of threonine 342 in helix 7 of the 5-hydroxytryptamine type 1D receptor in ligand binding: an indirect mechanism for receptor selectivity.
      A Smolyar and R Osman
      Molecular Pharmacology October 1993, 44 (4) 882-885;

T

  1. Takashima, H

    1. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442.
      S Yuasa, Y Sadakata, H Takashima, K Sekiya, N Inouye, M Ubasawa and M Baba
      Molecular Pharmacology October 1993, 44 (4) 895-900;

  2. Taylor, J E

    1. Discovery of a novel class of neuromedin B receptor antagonists, substituted somatostatin analogues.
      M Orbuch, J E Taylor, D H Coy, J E Mrozinski, S A Mantey, J F Battey, J P Moreau and R T Jensen
      Molecular Pharmacology October 1993, 44 (4) 841-850;

  3. Taylor, L P

    1. Antisera against peptides derived from a purified mu-opioid binding protein recognize the protein as well as mu-opioid receptors in brain regions and a cell line.
      T L Gioannini, Y H Yao, J M Hiller, L P Taylor and E J Simon
      Molecular Pharmacology October 1993, 44 (4) 796-801;

  4. Thanabal, V

    1. Structure and properties of omega-agatoxin IVB, a new antagonist of P-type calcium channels.
      M E Adams, I M Mintz, M D Reily, V Thanabal and B P Bean
      Molecular Pharmacology October 1993, 44 (4) 681-688;

  5. Timmerman, H

    1. New activation model for the histamine H2 receptor, explaining the activity of the different classes of histamine H2 receptor agonists.
      J C Eriks, H van der Goot and H Timmerman
      Molecular Pharmacology October 1993, 44 (4) 886-894;

  6. Turlin, B

    1. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture.
      Z Abdel-Razzak, P Loyer, A Fautrel, J C Gautier, L Corcos, B Turlin, P Beaune and A Guillouzo
      Molecular Pharmacology October 1993, 44 (4) 707-715;

U

  1. Ubasawa, M

    1. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442.
      S Yuasa, Y Sadakata, H Takashima, K Sekiya, N Inouye, M Ubasawa and M Baba
      Molecular Pharmacology October 1993, 44 (4) 895-900;

V

  1. van der Goot, H

    1. New activation model for the histamine H2 receptor, explaining the activity of the different classes of histamine H2 receptor agonists.
      J C Eriks, H van der Goot and H Timmerman
      Molecular Pharmacology October 1993, 44 (4) 886-894;

  2. Vonvoigtlander, P F

    1. Potentiation of gamma-aminobutyric acid-induced chloride currents by various benzodiazepine site agonists with the alpha 1 gamma 2, beta 2 gamma 2 and alpha 1 beta 2 gamma 2 subtypes of cloned gamma-aminobutyric acid type A receptors.
      H K Im, W B Im, B J Hamilton, D B Carter and P F Vonvoigtlander
      Molecular Pharmacology October 1993, 44 (4) 866-870;

W

  1. Weight, F F

    1. Ethanol inhibits a neuronal ATP-gated ion channel.
      C Li, L Aguayo, R W Peoples and F F Weight
      Molecular Pharmacology October 1993, 44 (4) 871-875;

  2. Weiss, M C

    1. The phenobarbital-induced transcriptional activation of cytochrome P-450 genes is blocked by the glucocorticoid-progesterone antagonist RU486.
      P M Shaw, M Adesnik, M C Weiss and L Corcos
      Molecular Pharmacology October 1993, 44 (4) 775-783;

  3. Wilcox, R A

    1. Inositol-1,3,4,5-tetrakisphosphate induces calcium mobilization via the inositol-1,4,5-trisphosphate receptor in SH-SY5Y neuroblastoma cells.
      R A Wilcox, R A Challiss, C Liu, B V Potter and S R Nahorski
      Molecular Pharmacology October 1993, 44 (4) 810-817;

  4. Williams, K

    1. Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor: selectivity and mechanisms at recombinant heteromeric receptors.
      K Williams
      Molecular Pharmacology October 1993, 44 (4) 851-859;

  5. Wistrand, P J

    1. Chemical properties of carbonic anhydrase IV, the membrane-bound enzyme.
      T H Maren, G C Wynns and P J Wistrand
      Molecular Pharmacology October 1993, 44 (4) 901-905;

  6. Wynns, G C

    1. Chemical properties of carbonic anhydrase IV, the membrane-bound enzyme.
      T H Maren, G C Wynns and P J Wistrand
      Molecular Pharmacology October 1993, 44 (4) 901-905;

Y

  1. Yao, Y H

    1. Antisera against peptides derived from a purified mu-opioid binding protein recognize the protein as well as mu-opioid receptors in brain regions and a cell line.
      T L Gioannini, Y H Yao, J M Hiller, L P Taylor and E J Simon
      Molecular Pharmacology October 1993, 44 (4) 796-801;

  2. Yu, H J

    1. Calcium entry via L-type calcium channels acts as a negative regulator of adenylyl cyclase activity and cyclic AMP levels in cardiac myocytes.
      H J Yu, H Ma and R D Green
      Molecular Pharmacology October 1993, 44 (4) 689-693;

  3. Yuasa, S

    1. Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442.
      S Yuasa, Y Sadakata, H Takashima, K Sekiya, N Inouye, M Ubasawa and M Baba
      Molecular Pharmacology October 1993, 44 (4) 895-900;
Back to top

In this issue